• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

乳头状肾癌的全基因组分析发现显著的非编码改变。

Whole-genome analysis of papillary kidney cancer finds significant noncoding alterations.

作者信息

Li Shantao, Shuch Brian M, Gerstein Mark B

机构信息

Program in Computational Biology and Bioinformatics, Yale University, New Haven, Connecticut, United States of America.

Department of Urology, Yale School of Medicine, New Haven, Connecticut, United States of America.

出版信息

PLoS Genet. 2017 Mar 30;13(3):e1006685. doi: 10.1371/journal.pgen.1006685. eCollection 2017 Mar.

DOI:10.1371/journal.pgen.1006685
PMID:28358873
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5391127/
Abstract

To date, studies on papillary renal-cell carcinoma (pRCC) have largely focused on coding alterations in traditional drivers, particularly the tyrosine-kinase, Met. However, for a significant fraction of tumors, researchers have been unable to determine a clear molecular etiology. To address this, we perform the first whole-genome analysis of pRCC. Elaborating on previous results on MET, we find a germline SNP (rs11762213) in this gene predicting prognosis. Surprisingly, we detect no enrichment for small structural variants disrupting MET. Next, we scrutinize noncoding mutations, discovering potentially impactful ones associated with MET. Many of these are in an intron connected to a known, oncogenic alternative-splicing event; moreover, we find methylation dysregulation nearby, leading to a cryptic promoter activation. We also notice an elevation of mutations in the long noncoding RNA NEAT1, and these mutations are associated with increased expression and unfavorable outcome. Finally, to address the origin of pRCC heterogeneity, we carry out whole-genome analyses of mutational processes. First, we investigate genome-wide mutational patterns, finding they are governed mostly by methylation-associated C-to-T transitions. We also observe significantly more mutations in open chromatin and early-replicating regions in tumors with chromatin-modifier alterations. Finally, we reconstruct cancer-evolutionary trees, which have markedly different topologies and suggested evolutionary trajectories for the different subtypes of pRCC.

摘要

迄今为止,关于乳头状肾细胞癌(pRCC)的研究主要集中在传统驱动因子的编码改变上,尤其是酪氨酸激酶Met。然而,对于相当一部分肿瘤,研究人员尚未能确定明确的分子病因。为了解决这一问题,我们对pRCC进行了首次全基因组分析。基于之前关于MET的研究结果,我们在该基因中发现了一个预测预后的种系单核苷酸多态性(rs11762213)。令人惊讶的是,我们未检测到破坏MET的小结构变异的富集。接下来,我们仔细研究非编码突变,发现了与MET相关的潜在影响性突变。其中许多位于与已知致癌性可变剪接事件相连的内含子中;此外,我们还发现附近存在甲基化失调,导致隐蔽启动子激活。我们还注意到长链非编码RNA NEAT1中的突变增加,这些突变与表达增加和不良预后相关。最后,为了探究pRCC异质性的起源,我们对突变过程进行了全基因组分析。首先,我们研究全基因组突变模式,发现它们主要受甲基化相关的C到T转换的控制。我们还观察到,在具有染色质修饰改变的肿瘤中,开放染色质和早期复制区域的突变明显更多。最后,我们重建了癌症进化树,不同亚型的pRCC具有明显不同的拓扑结构和进化轨迹。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5031/5391127/30efe21e4476/pgen.1006685.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5031/5391127/d14d9e91bacb/pgen.1006685.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5031/5391127/0cf6d535eb9d/pgen.1006685.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5031/5391127/ac634ec302e4/pgen.1006685.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5031/5391127/30efe21e4476/pgen.1006685.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5031/5391127/d14d9e91bacb/pgen.1006685.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5031/5391127/0cf6d535eb9d/pgen.1006685.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5031/5391127/ac634ec302e4/pgen.1006685.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5031/5391127/30efe21e4476/pgen.1006685.g004.jpg

相似文献

1
Whole-genome analysis of papillary kidney cancer finds significant noncoding alterations.乳头状肾癌的全基因组分析发现显著的非编码改变。
PLoS Genet. 2017 Mar 30;13(3):e1006685. doi: 10.1371/journal.pgen.1006685. eCollection 2017 Mar.
2
Papillary renal cell carcinoma: analysis of germline mutations in the MET proto-oncogene in a clinic-based population.乳头状肾细胞癌:基于临床人群的MET原癌基因种系突变分析
Genet Test. 2001 Summer;5(2):101-6. doi: 10.1089/109065701753145547.
3
MET alterations in biphasic squamoid alveolar papillary renal cell carcinomas and clinicopathological features.MET 改变在双相型鳞状肺泡状乳头状肾细胞癌中的表现及其临床病理特征。
Mod Pathol. 2021 Mar;34(3):647-659. doi: 10.1038/s41379-020-0645-6. Epub 2020 Aug 7.
4
Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma.MET基因变体rs11762213作为透明细胞肾细胞癌不良预后预测指标的验证及基因组分析
Cancer. 2016 Feb 1;122(3):402-10. doi: 10.1002/cncr.29765. Epub 2015 Oct 27.
5
Characterization of genetically defined sporadic and hereditary type 1 papillary renal cell carcinoma cell lines.遗传性和散发性 1 型乳头状肾细胞癌细胞系的基因特征分析。
Genes Chromosomes Cancer. 2021 Jun;60(6):434-446. doi: 10.1002/gcc.22940. Epub 2021 Mar 10.
6
MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression array.MET 是所有乳头状肾细胞癌的潜在靶点:来自大规模乳头状肾细胞癌 CGH 阵列和匹配基因表达阵列的分子研究结果。
Clin Cancer Res. 2014 Jul 1;20(13):3411-21. doi: 10.1158/1078-0432.CCR-13-2173. Epub 2014 Mar 21.
7
Papillary renal cell carcinoma: a clinicopathological and whole-genome exon sequencing study.乳头状肾细胞癌:一项临床病理与全基因组外显子测序研究
Int J Clin Exp Pathol. 2015 Jul 1;8(7):8311-35. eCollection 2015.
8
Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes.多种基因组改变谱定义了非透明细胞肾细胞癌亚型。
Nat Genet. 2015 Jan;47(1):13-21. doi: 10.1038/ng.3146. Epub 2014 Nov 17.
9
Papillary renal cell carcinoma with a somatic mutation in MET in a patient with autosomal dominant polycystic kidney disease.一名患有常染色体显性遗传性多囊肾病的患者,其乳头状肾细胞癌存在MET基因的体细胞突变。
Cancer Genet. 2016 Jan-Feb;209(1-2):11-20. doi: 10.1016/j.cancergen.2015.11.002. Epub 2015 Dec 1.
10
Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family.一个遗传性乳头状肾细胞癌(HPRCC)家系中MET原癌基因酪氨酸激酶ATP结合位点的新突变。
Int J Cancer. 1999 Aug 27;82(5):640-3. doi: 10.1002/(sici)1097-0215(19990827)82:5<640::aid-ijc4>3.0.co;2-6.

引用本文的文献

1
Long noncoding RNA MEG8 induces an imbalance of Th17/Treg cells through the miR-107/STAT3 axis in Henoch-Schonlein purpura rats.长链非编码 RNA MEG8 通过 miR-107/STAT3 轴诱导 Henoch-Schonlein 紫癜大鼠 Th17/Treg 细胞失衡。
Aging (Albany NY). 2023 Dec 4;15(23):13854-13864. doi: 10.18632/aging.205266.
2
The roles of long non‑coding RNAs in renal cell carcinoma (Review).长链非编码RNA在肾细胞癌中的作用(综述)
Mol Clin Oncol. 2022 Nov 28;18(1):4. doi: 10.3892/mco.2022.2600. eCollection 2023 Jan.
3
NEAT1 can be a diagnostic biomarker in the breast cancer and gastric cancer patients by targeting XIST, hsa-miR-612, and MTRNR2L8: integrated RNA targetome interaction and experimental expression analysis.

本文引用的文献

1
Endogenous retroviral promoter exaptation in human cancer.人类癌症中内源性逆转录病毒启动子的适应性进化
Mob DNA. 2016 Dec 1;7:24. doi: 10.1186/s13100-016-0080-x. eCollection 2016.
2
Analysis of protein-coding genetic variation in 60,706 humans.对60706名人类的蛋白质编码基因变异进行分析。
Nature. 2016 Aug 18;536(7616):285-91. doi: 10.1038/nature19057.
3
Landscape of somatic mutations in 560 breast cancer whole-genome sequences.560例乳腺癌全基因组序列中的体细胞突变图谱。
通过靶向XIST、hsa-miR-612和MTRNR2L8:综合RNA靶标组相互作用及实验表达分析,NEAT1可作为乳腺癌和胃癌患者的诊断生物标志物。
Genes Environ. 2022 May 17;44(1):16. doi: 10.1186/s41021-022-00244-3.
4
Non-coding driver mutations in human cancer.人类癌症中的非编码驱动突变。
Nat Rev Cancer. 2021 Aug;21(8):500-509. doi: 10.1038/s41568-021-00371-z. Epub 2021 Jul 6.
5
Whole-genome sequencing of phenotypically distinct inflammatory breast cancers reveals similar genomic alterations to non-inflammatory breast cancers.表型不同的炎性乳腺癌的全基因组测序揭示了与非炎性乳腺癌相似的基因组改变。
Genome Med. 2021 Apr 26;13(1):70. doi: 10.1186/s13073-021-00879-x.
6
lncRNA NEAT1 ameliorates LPS‑induced inflammation in MG63 cells by activating autophagy and suppressing the NLRP3 inflammasome.长链非编码 RNA NEAT1 通过激活自噬和抑制 NLRP3 炎性小体减轻 LPS 诱导的 MG63 细胞炎症。
Int J Mol Med. 2021 Feb;47(2):607-620. doi: 10.3892/ijmm.2020.4827. Epub 2020 Dec 22.
7
Development of an Autophagy Score Signature for Predicting Overall Survival in Papillary Renal Cell Carcinoma.自噬评分特征的建立用于预测肾乳头状细胞癌的总生存期。
Dis Markers. 2020 Nov 9;2020:8867019. doi: 10.1155/2020/8867019. eCollection 2020.
8
Discovery of driver non-coding splice-site-creating mutations in cancer.在癌症中发现驱动性非编码剪接位点创造突变。
Nat Commun. 2020 Nov 4;11(1):5573. doi: 10.1038/s41467-020-19307-6.
9
c-Met expression in renal cell carcinoma with bone metastases.c-Met在伴有骨转移的肾细胞癌中的表达。
J Bone Oncol. 2020 Sep 16;25:100315. doi: 10.1016/j.jbo.2020.100315. eCollection 2020 Dec.
10
A SNP-mediated lncRNA (LOC146880) and microRNA (miR-539-5p) interaction and its potential impact on the NSCLC risk.SNP 介导的长链非编码 RNA(LOC146880)和 microRNA(miR-539-5p)相互作用及其对 NSCLC 风险的潜在影响。
J Exp Clin Cancer Res. 2020 Aug 14;39(1):157. doi: 10.1186/s13046-020-01652-5.
Nature. 2016 Jun 2;534(7605):47-54. doi: 10.1038/nature17676. Epub 2016 May 2.
4
The real cost of sequencing: scaling computation to keep pace with data generation.测序的实际成本:扩展计算能力以跟上数据生成的步伐。
Genome Biol. 2016 Mar 23;17:53. doi: 10.1186/s13059-016-0917-0.
5
Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma.基于多组学的肾细胞癌分类法
Cell Rep. 2016 Mar 15;14(10):2476-89. doi: 10.1016/j.celrep.2016.02.024. Epub 2016 Mar 3.
6
Mutational Strand Asymmetries in Cancer Genomes Reveal Mechanisms of DNA Damage and Repair.癌症基因组中的突变链不对称揭示DNA损伤与修复机制。
Cell. 2016 Jan 28;164(3):538-49. doi: 10.1016/j.cell.2015.12.050. Epub 2016 Jan 21.
7
An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma.透明细胞肾细胞癌的综合代谢图谱
Cancer Cell. 2016 Jan 11;29(1):104-116. doi: 10.1016/j.ccell.2015.12.004.
8
Aberrant NEAT1 expression is associated with clinical outcome in high grade glioma patients.异常的NEAT1表达与高级别胶质瘤患者的临床预后相关。
APMIS. 2016 Mar;124(3):169-74. doi: 10.1111/apm.12480. Epub 2015 Nov 19.
9
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma.乳头状肾细胞癌的综合分子特征分析
N Engl J Med. 2016 Jan 14;374(2):135-45. doi: 10.1056/NEJMoa1505917. Epub 2015 Nov 4.
10
A mutational signature in gastric cancer suggests therapeutic strategies.胃癌中的一种突变特征提示了治疗策略。
Nat Commun. 2015 Oct 29;6:8683. doi: 10.1038/ncomms9683.